RCKT INVESTOR DEADLINE: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit

Core Viewpoint - A class action lawsuit has been filed against Rocket Pharmaceuticals, alleging violations of the Securities Exchange Act of 1934 related to misleading information about the company's clinical trials and safety protocols [1][4][5]. Company Overview - Rocket Pharmaceuticals operates as a late-stage biotechnology company focused on developing gene therapies for rare and devastating diseases [3]. Allegations of the Lawsuit - The lawsuit claims that Rocket Pharmaceuticals provided investors with misleading information regarding the Phase 2 pivotal trial of RP-A501 for Danon disease, while concealing material adverse facts about the safety and clinical trial protocol [4]. - It is alleged that the company failed to disclose serious adverse events, including participant deaths, and made substantive amendments to the trial protocol without informing shareholders [4][5]. - Following the announcement of a clinical hold by the U.S. Food and Drug Administration due to a serious adverse event, the stock price of Rocket Pharmaceuticals reportedly fell [5]. Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Rocket Pharmaceuticals securities during the class period to seek appointment as lead plaintiff in the lawsuit [6]. - The lead plaintiff represents the interests of all class members and can select a law firm to litigate the case [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [7].